Prosecution Insights
Last updated: August 11, 2026
Application No. 15/765,960

COMPOUNDS AND COMPOSITIONS HAVING KNOCK-DOWN OR BLOOD FEED INHIBITION ACTIVITY AGAINST INSECT PESTS

Non-Final OA §112
Filed
Apr 04, 2018
Priority
Oct 06, 2015 — provisional 62/238,050 +1 more
Examiner
CHONG, YONG SOO
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Syngenta AG
OA Round
4 (Non-Final)
44%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
85%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
385 granted / 881 resolved
-16.3% vs TC avg
Strong +42% interview lift
Without
With
+41.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
52 currently pending
Career history
945
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
53.0%
+13.0% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
17.5%
-22.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 881 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/17/26 has been entered. Claims 26-34, 39-45 are pending and examined herein. Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112(b): The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 45 is rejected under 35 U.S.C. 112(b) or 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, claim 45 recites the limitation "the mosquito insecticide resistant" in claim 26. There is insufficient antecedent basis for this limitation in the claims. The Examiner notes that if the limitation is amended to “the mosquito is insecticide resistant” the rejection would be withdrawn. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong S. Chong whose telephone number is (571)-272-8513. The examiner can normally be reached Monday to Friday: 9 AM to 5 PM EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan, can be reached at (571)-270-7674. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866)-217-9197 (toll-free). /Yong S. Chong/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Show 23 earlier events
Jul 03, 2025
Response Filed
Sep 25, 2025
Examiner Interview (Telephonic)
Jan 07, 2026
Request for Continued Examination
Jan 13, 2026
Response after Non-Final Action
Apr 17, 2026
Request for Continued Examination
Apr 20, 2026
Response after Non-Final Action
May 01, 2026
Non-Final Rejection mailed — §112
Aug 03, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12691087
METHOD OF ENHANCING GLUCOSE LEVELS IN THE CENTRAL NERVOUS SYSTEM
7y 1m to grant Granted Jul 28, 2026
Patent 12686657
ANTI-INFLAMMATORY CARBOXAMIDE DERIVATIVES
2y 10m to grant Granted Jul 21, 2026
Patent 12673062
COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER
5y 9m to grant Granted Jul 07, 2026
Patent 12673034
PEPTIDES, COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING SOX9
4y 1m to grant Granted Jul 07, 2026
Patent 12667566
COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS
4y 5m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
44%
Grant Probability
85%
With Interview (+41.7%)
3y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 881 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month